Integra LifeSciences (NASDAQ:IART) Price Target Lowered to $19.00 at Truist Financial

Integra LifeSciences (NASDAQ:IART) had its price objective lowered by Truist Financial from $26.00 to $19.00 in a research note released on Friday,Benzinga reports. The firm currently has a hold rating on the life sciences company’s stock.

Separately, Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Monday, March 31st. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $22.71.

Integra LifeSciences Stock Performance

NASDAQ IART opened at $16.99 on Friday. Integra LifeSciences has a 52-week low of $15.95 and a 52-week high of $33.04. The stock has a market cap of $1.31 billion, a PE ratio of -188.76, a P/E/G ratio of 0.73 and a beta of 1.24. The firm has a 50-day moving average of $22.28 and a 200-day moving average of $22.34. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. During the same period last year, the business posted $0.89 earnings per share. The business’s revenue for the quarter was up 11.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership increased its holdings in Integra LifeSciences by 7.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company’s stock valued at $312,000 after buying an additional 913 shares during the period. Quadrant Capital Group LLC boosted its position in shares of Integra LifeSciences by 5,960.9% during the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 1,371 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Integra LifeSciences by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company’s stock valued at $872,000 after acquiring an additional 1,437 shares during the last quarter. Sterling Capital Management LLC raised its position in Integra LifeSciences by 821.7% during the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock valued at $49,000 after purchasing an additional 1,931 shares in the last quarter. Finally, Covestor Ltd lifted its stake in Integra LifeSciences by 61.8% during the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company’s stock worth $123,000 after purchasing an additional 2,071 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.